Consequently, they hope that their results will «motivate the incorporation of assays measuring ex-vivo T - cell function into
ongoing and planned clinical trials of HDAC inhibitors, and that
immunosuppression will be considered as a potential factor limiting the effectiveness of any observed outcomes.»